A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion

Zonghui Ding, Alison Roos, Jean Kloss, Harshil Dhruv, Sen Peng, Patrick Pirrotte, Jennifer M. Eschbacher, Nhan Tran, Joseph C Loftus

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-kB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion.

Original languageEnglish (US)
Pages (from-to)322-332
Number of pages11
JournalMolecular Cancer Research
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Glioblastoma
temozolomide
Neoplasms
Epidermal Growth Factor
Survival
NF-kappa B
Tumor Necrosis Factor Receptors
Heterografts
Brain Neoplasms
Neuroglia
Cysteine
Radiotherapy
Radiation
Recurrence
Drug Therapy
Brain
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion. / Ding, Zonghui; Roos, Alison; Kloss, Jean; Dhruv, Harshil; Peng, Sen; Pirrotte, Patrick; Eschbacher, Jennifer M.; Tran, Nhan; Loftus, Joseph C.

In: Molecular Cancer Research, Vol. 16, No. 2, 01.02.2018, p. 322-332.

Research output: Contribution to journalArticle

Ding, Zonghui ; Roos, Alison ; Kloss, Jean ; Dhruv, Harshil ; Peng, Sen ; Pirrotte, Patrick ; Eschbacher, Jennifer M. ; Tran, Nhan ; Loftus, Joseph C. / A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion. In: Molecular Cancer Research. 2018 ; Vol. 16, No. 2. pp. 322-332.
@article{bed2f440e420427abc9548bc5c08faa9,
title = "A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion",
abstract = "Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-kB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion.",
author = "Zonghui Ding and Alison Roos and Jean Kloss and Harshil Dhruv and Sen Peng and Patrick Pirrotte and Eschbacher, {Jennifer M.} and Nhan Tran and Loftus, {Joseph C}",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/1541-7786.MCR-17-0454",
language = "English (US)",
volume = "16",
pages = "322--332",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion

AU - Ding, Zonghui

AU - Roos, Alison

AU - Kloss, Jean

AU - Dhruv, Harshil

AU - Peng, Sen

AU - Pirrotte, Patrick

AU - Eschbacher, Jennifer M.

AU - Tran, Nhan

AU - Loftus, Joseph C

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-kB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion.

AB - Glioblastoma is the most frequent primary brain tumor in adults and a highly lethal malignancy with a median survival of about 15 months. The aggressive invasion of the surrounding normal brain makes complete surgical resection impossible, increases the resistance to radiation and chemotherapy, and assures tumor recurrence. Thus, there is an urgent need to develop innovative therapeutics to target the invasive tumor cells for improved treatment outcomes of this disease. Expression of TROY (TNFRSF19), a member of the tumor necrosis factor (TNF) receptor family, increases with increasing glial tumor grade and inversely correlates with patient survival. Increased expression of TROY stimulates glioblastoma cell invasion in vitro and in vivo and increases resistance to temozolomide and radiation therapy. Conversely, silencing TROY expression inhibits glioblastoma cell invasion, increases temozolomide sensitivity, and prolongs survival in an intracranial xenograft model. Here, a novel complex is identified between TROY and EGFR, which is mediated predominantly by the cysteine-rich CRD3 domain of TROY. Glioblastoma tumors with elevated TROY expression have a statistically positive correlation with increased EGFR expression. TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion. Mechanistically, TROY expression modulates EGFR signaling by facilitating EGFR activation and delaying EGFR receptor internalization. Moreover, the association of EGFR with TROY increases TROY-induced NF-kB activation. These findings substantiate a critical role for the TROY–EGFR complex in regulation of glioblastoma cell invasion. Implications: The TROY–EGFR signaling complex emerges as a potential therapeutic target to inhibit glioblastoma cell invasion.

UR - http://www.scopus.com/inward/record.url?scp=85041478574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041478574&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-17-0454

DO - 10.1158/1541-7786.MCR-17-0454

M3 - Article

VL - 16

SP - 322

EP - 332

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 2

ER -